What should define a SARS-CoV-2 "breakthrough" infection?

Schieffelin, John S; Norton, Elizabeth B; Kolls, Jay K

Schieffelin, John S; Norton, Elizabeth B; Kolls, Jay K.

Schieffelin JS; Tulane Department of Pediatrics.
Norton EB; Tulane Department of Microbiology and Immunology, and.
Kolls JK; Center for Translational Research in Infection and Inflammation, Tulane School of Medicine, New Orleans, Louisiana, USA.

J Clin Invest ; 131(12)2021 06 15.

Article in English | MEDLINE | ID: covidwho-1223645

Subject(s)

COVID-19 Vaccines/therapeutic use; COVID-19/prevention & control; Immunity, Mucosal/drug effects; SARS-CoV-2/immunology; COVID-19/epidemiology; COVID-19/immunology; COVID-19/pathology; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunity, Mucosal / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Language: English Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google